home ver. 2.3. site index contact us

Message from the CEO
How We Work
History of Schering-Plough
Management Team
Schering-Plough Worldwide
Speeches & Presentations
The Schering-Plough Foundation
Diversity & Inclusion
Workforce Diversity
Supplier Diversity
Supplier Registration

Creating Value from Diversity

For Schering-Plough, innovation has become a primary differentiator and driver of performance. We believe that diversity fuels innovation.

Research shows that a multicultural work force offers a richer variety of approaches to work-related problems and processes. Ensuring that a diversity of opinions, experiences, cultures and perspectives are represented, and fostering an environment that allows them to flourish, creates the essential breeding ground for innovation.

As we focus our research efforts on developing innovative medicines, we are at the same time focused on finding ways to maximize the potential of our own diverse work force. By doing so, we're creating value from our diversity.

This philosophy - looking at diversity as an essential driver of our success - has led us to dedicate ourselves to the following vision and mission:

Diversity and inclusion vision - A new kind of health care company, best among its peers, that is global in structure and outlook, diverse and inclusive in its culture

Diversity and inclusion mission - To build leadership and organizational capacity and capability to create value out of our global dimensions of diversity and inclusion

Spotlight On

Combination Brochure

Brochure on the Combination

Basic Facts and Figures
•  World Headquarters:
2000 Galloping Hill Road, Kenilworth, N.J. 07033-0530
•  Chairman and CEO:
Fred Hassan
Number of employees:
55,000
Net sales (2007):
$12.7 billion
Business operations in more than:
140 countries
Largest-selling products:
VYTORIN*, ZETIA*, REMICADE, NASONEX.
R&D investment (2007):
$2.9 billion
Areas of research:
cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology, respiratory diseases and women's health

*VYTORIN and ZETIA are managed through a joint venture with Merck & Co., Inc. Schering-Plough accounts for the joint venture under the Equity method. Total cholesterol joint venture sales were $5.2 billion in 2007.
 
                                      © 2003-2008 Schering-Plough Corporation.
                 Please see our legal notice, privacy policy and forward-looking statement.
Schering-Plough Schering-Plough skip to content Schering-Plough